Vascepa

Amarin Corporation (NASDAQ: AMRN) presented data for its cardiovascular outcome study of its prescription Vascepa (icosapent ethyl), the REDUCE-IT study. Vascepa demonstrated a statistically significant 30 percent risk reduction in cardiovascular events compared to placebo in the statin-treated...

Amarin Corporation plc (NASDAQ: AMRN) shares were falling Monday following the presentation of detailed primary results from the the late-stage REDUCE-IT study that evaluated Vascepa, held at a late-breaking session at the 2018 Scientific Sessions of the American Heart Association in Chicago....

Amarin Corp. (NASDAQ: AMRN) shares surged Monday after the company reported positive cardiovascular trial results for its fish oil capsules.   The Analyst H.C. Wainwright & Co. analyst Andrew S. Fein reiterated a Buy rating on Amarin and raised the price target from $10 to $...

Amarin Corporation plc (NASDAQ: AMRN) stock more than tripled Monday after its latest study results showed the company’s fish oil capsules significantly reduce the risk of cardiovascular events. What Happened? Amarin reported Monday that its Vascepa fish oil capsule reduced the risk...

Is Amarin's (NASDAQ: AMRN) Vascepa the victim of its own ineptitude, or the target of an effort by Big Pharma to keep it off the market? Those questions and others have been lobbed around lately by a variety of industry observers and investors, regarding Amarin's sole product, Vascepa – a...

Trading in shares of Amarin (NASDAQ: AMRN) has been muted on Friday despite the expectation for high levels of volatility after the stock plunged 20 percent in Thursday's after hours trading session. It would appear that the stock has found equilibrium after the big after hours decline, because...